Very good points
There is no effective link between the Board and the product champions and no direct interface with the investment community.
I guess we'll never know the reason why Washer left....But what I do know about small Aussie biotechs is that you often see the same people cropping up on the Boards of other small biotechs....journeymen directors more often concerned with their own interests than those of the general shareholder body
